470689-87-3

Usage

Uses

Used in Pharmaceutical Development:
(2,4-diMethyl-1-oxypyridin-3-yl)[4'-Methyl-4-(phenylpyridin-3-ylaMino)-[1,4']bipiperidinyl-1'-yl]-Methanone is used as a potential pharmaceutical agent due to its complex structure and the presence of functional groups that may contribute to biological activity.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2,4-diMethyl-1-oxypyridin-3-yl)[4'-Methyl-4-(phenylpyridin-3-ylaMino)-[1,4']bipiperidinyl-1'-yl]-Methanone is utilized for its potential to interact with biological targets, offering a foundation for the design of new drugs and therapeutic agents.

Upstream product

• 1024615-31-3 4-(phenylpyridin-3-ylamino)piperidine-1-carboxylic acid tert-butyl ester 
• 470690-10-9 phenylpiperidin-4-ylpyridin-3-ylamine 
• 62-53-3 aniline 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 125541-22-2 1-(tert-butoxycarbonyl)-4-phenylaminopiperidine 
• 678975-17-2 (4'-methyl-[1,4′]bipiperidinyl-4-yl)phenylpyridin-3-ylamine 
• 372156-99-5 3-carboxy-2,4-dimethylpyridine 1-oxide 

Relevant academic research and scientific papers

A scalable synthesis of an atropisomeric drug substance via buchwald-hartwig amination and bruylants reactions

A practical, chromatography-free synthesis for a chemokine receptor antagonist NIBR-1282 (1) is described. Highlights of this scalable synthesis include (1) Buchwald-Hartwig amination reaction using (t-Bu)3P as the ligand and 5-12 mol % of water as an additive affording 6 with yield increase of more than 2-fold; (2) a variant of the Bruylants reaction for the synthesis of a-methyl amine 10 via aminotriazole 15a, instead of classical amino nitrile 8; and (3) development of a crystallization-induced, atropisomer transformation leading to predominantly one atropisomer 1. The new approach was employed for the manufacturing of kilogram quantities of the target active pharmaceutical ingredient.

Reduced cardiac side-effect potential by introduction of polar groups: Discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo

Introduction of polar groups in a series of potent CCR5 antagonists which are very likely to adversely affect the conduction system in the heart led to the identification of NIBR-1282 which did not show adverse effects when tested in an isolated rabbit heart ex vivo model. Administration of NIBR-1282 in combination with a non-efficacious dose of CsA led to significant prolongation of kidney allograft survival in cynomolgus monkeys.